Literature DB >> 10411108

Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat.

R B Howard1, J B Mullen, M E Pagura, M R Johnston.   

Abstract

The prevailing subcutaneous nude rodent tumor xenograft models used for biological and preclinical studies do not optimally reflect some important biological properties of cancer, especially invasion and metastasis. Orthotopic models have been developed to address this need. However, for lung cancer none of the available models are optimal, in that none originate from an orthotopic (bronchial) primary site and exhibit extensive extrathoracic metastasis. Our goal was to develop a consistent rodent model of non-small cell lung cancer with both of these properties. Groups of male Rowett nude rats were given 500 rads of gamma radiation and then endobronchially implanted in the right caudal lobe airway with 50 mg of small NCI-H460 tumor fragments taken from an orthotopic donor tumor. They were then sacrificed at selected post-implantation times and evaluated grossly and histologically for animal weight, primary tumor take and size, and metastatic tumor incidence at multiple sites. At a late time point (32-35 days), consistency of primary tumor size and metastasis was estimated by comparing results from four groups of rats implanted on different occasions. The results showed that the primary tumors grew steadily, reaching four grams by days 32-35. Rats gained weight until days 14 to 21, but then began to show cachexia. High metastatic rates (>60%) were seen for mediastinal lymph nodes (by 21 days), and kidney, bone and brain (by 28 days). Mean primary tumor size and the incidences of both regional and systemic metastasis were consistent at 32-35 days in four different groups of six animals. In conclusion, this orthotopic lung cancer model is highly metastatic and consistent in terms of both primary tumor growth and metastatic behavior. It is the only available rodent model of human lung cancer emanating from an endobronchial site and metastasizing to multiple extrapulmonary sites, and should be very useful for both biological and preclinical studies of lung cancer, particularly where studies of antimetastatic activity are of interest, and/or where survival studies are desired.

Entities:  

Mesh:

Year:  1999        PMID: 10411108     DOI: 10.1023/a:1006637712294

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  19 in total

1.  Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.

Authors:  F M Marincola; L F Da Pozzo; B J Drucker; W D Holder
Journal:  Surgery       Date:  1990-11       Impact factor: 3.982

Review 2.  Inhibitors of angiogenesis.

Authors:  M A Moses; R Langer
Journal:  Biotechnology (N Y)       Date:  1991-07

3.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

4.  Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected].

Authors:  I J Fidler; S Naito; S Pathak
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

5.  Orthotopic reconstitution of human small-cell lung carcinoma after intravenous transplantation in SCID mice.

Authors:  T H Kuo; T Kubota; M Watanabe; T Furukawa; S Kase; H Tanino; H Nishibori; Y Saikawa; T Teramoto; K Ihsibiki
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

6.  A new patient-like metastatic model of human small-cell lung cancer constructed orthotopically with intact tissue via thoracotomy in nude mice.

Authors:  X Wang; X Fu; T Kubota; R M Hoffman
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

7.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.

Authors:  B Davies; P D Brown; N East; M J Crimmin; F R Balkwill
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

8.  Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

Authors:  E Boven; B Winograd; D P Berger; M P Dumont; B J Braakhuis; O Fodstad; S Langdon; H H Fiebig
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

9.  Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy.

Authors:  P J Russell; I Ho Shon; G R Boniface; M E Izard; J Philips; D Raghavan; K Z Walker
Journal:  Urol Res       Date:  1991

10.  A patient-like metastasizing model of human lung adenocarcinoma constructed via thoracotomy in nude mice.

Authors:  X Wang; X Fu; R M Hoffman
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

View more
  10 in total

Review 1.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Stephanie Corn; Abraham Schneider; Laurie K McCauley
Journal:  Cancer Treat Res       Date:  2004

2.  A novel bioluminescence orthotopic mouse model for advanced lung cancer.

Authors:  Bo Li; Artour Torossian; Wenyan Li; Stephen Schleicher; Kathy Niu; Nicholas J Giacalone; Sung June Kim; Heidi Chen; Adriana Gonzalez; Luigi Moretti; Bo Lu
Journal:  Radiat Res       Date:  2011-06-10       Impact factor: 2.841

3.  Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.

Authors:  Nancy D Doolittle; David M Peereboom; Gregory A Christoforidis; Walter A Hall; Diane Palmieri; Penelope R Brock; Kathleen C M Campbell; D Thomas Dickey; Leslie L Muldoon; Brian Patrick O'Neill; Darryl R Peterson; Brad Pollock; Carole Soussain; Quentin Smith; Rose Marie Tyson; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2006-07-21       Impact factor: 4.130

Review 4.  Preclinical approaches to study the biology and treatment of brain metastases.

Authors:  William Cruz-Muñoz; Robert S Kerbel
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

5.  Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.

Authors:  Roya Navab; Jiang Liu; Isolde Seiden-Long; Warren Shih; Ming Li; Bizhan Bandarchi; Yan Chen; Davina Lau; Yen-Fen Zu; Dave Cescon; Chang Qi Zhu; Shawna Organ; Emin Ibrahimov; Dina Ohanessian; Ming-Sound Tsao
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  New orthotopic implantation model of human esophageal squamous cell carcinoma in athymic nude mice.

Authors:  Shuai Song; Dong Chang; Yong Cui; Jian Hu; Min Gong; Kai Ma; Fang Ding; Zhi-Hua Liu; Tian-You Wang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

Review 7.  Metastasis and cachexia: alongside in clinics, but not so in animal models.

Authors:  Rebeka Tomasin; Ana Carolina Baptista Moreno Martin; Márcia Regina Cominetti
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-08-22       Impact factor: 12.910

Review 8.  Skeletal metastasis: treatments, mouse models, and the Wnt signaling.

Authors:  Kenneth C Valkenburg; Matthew R Steensma; Bart O Williams; Zhendong Zhong
Journal:  Chin J Cancer       Date:  2013-01-18

9.  [An experimental study on the Chinese lung adenocarcinoma cell clone CPA-Yang1-BR with brain metastasis potency in nude mice and in vivo imaging research].

Authors:  Bei Lei; Jie Cao; Jie Shen; Lanxiang Zhao; Sheng Liang; Qinggang Meng; Wenhui Xie; Shunfang Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-08-20

10.  A novel transplantable model of lung cancer-associated tissue loss and disrupted muscle regeneration.

Authors:  Paige C Arneson-Wissink; Alexandra M Ducharme; Jason D Doles
Journal:  Skelet Muscle       Date:  2020-03-09       Impact factor: 4.912

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.